A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
In this 52-week trial involving participants with active SLE who were receiving background therapy, the incidence of a clinical response was higher with telitacicept than with placebo. However, the incidence of upper respiratory infections, reduced immunoglobulin levels, and injection-site reactions was also higher with telitacicept. (Funded by RemeGen; 18C010 ClinicalTrials.gov number, NCT04082416.).
Authors
- Lu Fang (ORCID: https://orcid.org/0000-0001-8235-6366)
- Hanyou Mo (ORCID: https://orcid.org/0000-0001-5482-5014)
- Ronald van Vollenhoven (ORCID: https://orcid.org/0000-0001-6438-8663)
- Dongbao Zhao
- Jianmin Fang (ORCID: https://orcid.org/0000-0002-4332-4967)
- Qing Zuraw
- Joan T. Merrill (ORCID: https://orcid.org/0000-0002-4514-2382)
- Cibo Huang (ORCID: https://orcid.org/0000-0001-6706-7750)
- LI Fen (ORCID: https://orcid.org/0000-0002-9009-2660)
- Wei Wei (ORCID: https://orcid.org/0000-0003-4066-0081)
- Yi Liu (ORCID: https://orcid.org/0000-0003-2004-9867)
- Li Wang (ORCID: https://orcid.org/0000-0002-5595-2741)
- Lin Li (ORCID: https://orcid.org/0000-0003-1578-9182)
- Wenxiang Wang (ORCID: https://orcid.org/0000-0001-8797-1413)
- Xuebin Wang (ORCID: https://orcid.org/0000-0002-8407-751X)
- Fengchun Zhang (ORCID: https://orcid.org/0000-0003-3484-4319)
- Jiankang Hu
- Xiaofei Wang (ORCID: https://orcid.org/0000-0002-3248-6805)
- Chunde Bao (ORCID: https://orcid.org/0000-0003-3178-1738)
- Jingyang Li (ORCID: https://orcid.org/0000-0001-8271-1575)
- Jianhong Zhao
- Chenghui Huang (ORCID: https://orcid.org/0009-0007-3045-4563)
Institutions
- Tongji University (CN)
- Binzhou Medical University (CN)
- Central South University (CN)
- Shandong University of Aeronautics (CN)
- Guilin Medical University (CN)
- Second Military Medical University (CN)
- Yantai University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- Renji Hospital (CN)
- Peking Union Medical College Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- Oklahoma Medical Research Foundation (US)
- West China Hospital of Sichuan University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Changhai Hospital (CN)
- Beijing Hospital (CN)
- Jiangxi Pingxiang People's Hospital (CN)
- Jining First People's Hospital (CN)
- Zhuzhou Central Hospital (CN)
- Remegenix (United States) (US)
- Second Xiangya Hospital of Central South University (CN)
- Baotou Medical College (CN)
- University of Oklahoma Health Sciences Center (US)
- University of Amsterdam (NL)
- China Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1056/nejmoa2414719
- Citations
- 11
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 18.35